Amplified segment in the 'Down syndrome critical region' on HSA21 shared between Down syndrome and euploid AML-M0 excludes RUNX1, ERG and ETS2

Br J Haematol. 2012 Apr;157(2):197-200. doi: 10.1111/j.1365-2141.2011.08985.x. Epub 2012 Jan 5.

Abstract

Children with Down syndrome have a 20- to 50-fold increased risk of acute lymphocytic or myeloid leukaemia. Whole or partial gains of chromosome 21 have been described in multiple childhood leukaemias, and have recently been reported as a likely primary event in B-precursor-acute lymphoblastic leukaemia. It is unclear which amplified gene(s) on chromosome 21 play a key role in leukaemia progression. We describe a minimal amplified segment within the so-called 'Down syndrome critical region' shared between two cases of AML-M0; a Down syndrome, and a constitutionally normal individual. Interestingly, the amplified region does not include the oncogenes RUNX1, ETS2 and ERG.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Core Binding Factor Alpha 2 Subunit / genetics*
  • Down Syndrome / genetics*
  • Female
  • Genetic Loci*
  • Humans
  • Leukemia, Myeloid, Acute / genetics*
  • Male
  • Proto-Oncogene Protein c-ets-2 / genetics*
  • Trans-Activators / genetics*
  • Transcriptional Regulator ERG

Substances

  • Core Binding Factor Alpha 2 Subunit
  • ERG protein, human
  • ETS2 protein, human
  • Proto-Oncogene Protein c-ets-2
  • RUNX1 protein, human
  • Trans-Activators
  • Transcriptional Regulator ERG